PTEN公司
前列腺癌
肿瘤科
阉割
医学
癌症
内科学
总体生存率
前列腺
妇科
生物
激素
细胞凋亡
PI3K/AKT/mTOR通路
生物化学
作者
Shilpa Gupta,Tu My To,Ryon P. Graf,Edward E. Kadel,Norelle R. Reilly,Husam Albarmawi
出处
期刊:JCO precision oncology
[American Society of Clinical Oncology]
日期:2024-03-01
卷期号: (8)
摘要
It is estimated that the PTEN tumor suppressor gene is functionally lost in 40%-50% of patients with metastatic castration-resistant prostate cancer (mCRPC). There is limited information on the prognostic significance of PTEN status identified with genomic testing. This real-world cohort study assessed PTEN as a genetic biomarker using data from US-based oncology practices.This retrospective real-world cohort study used a deidentified US-based metastatic prostate cancer clinicogenomic database linked to longitudinal clinical data derived from electronic health records. Patients were aged 18 years and older and diagnosed with mCRPC between January 1, 2018, and June 30, 2021. Comprehensive genomic profiling (CGP) of tumor specimens was performed using next-generation sequencing. First-line (1L) and second-line (2L) treatment patterns were assessed and stratified by PTEN status. Kaplan-Meier methods and a multivariable Cox model were used to compare the real-world overall survival by PTEN status among patients who received 1L novel hormone therapy or taxanes.In patients with mCRPC who underwent CGP, PTEN loss of function (LOF) was associated with decreased survival compared with intact PTEN (hazard ratio, 1.61 [95% CI, 1.07 to 2.42]; P = .024). The results were not influenced by 1L treatment type. 1L treatment patterns were similar between intact PTEN and PTEN LOF subgroups, with abiraterone and enzalutamide being the two most common treatments in both groups. Patients with PTEN LOF were less likely to receive 2L treatments than patients with intact PTEN.PTEN LOF, identified with genomic testing, was associated with decreased survival and negative prognoses in patients with mCRPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI